Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution in healthy adult male volunteers. -ocular blood flow measurements as efficacy endpoints-

Trial Profile

Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution in healthy adult male volunteers. -ocular blood flow measurements as efficacy endpoints-

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2016

At a glance

  • Drugs Tafluprost (Primary) ; Bunazosin
  • Indications Glaucoma
  • Focus Therapeutic Use
  • Sponsors Santen Pharmaceutical
  • Most Recent Events

    • 19 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top